Bellevue Group Reports CHF 1.8 Million Net Profit Despite Market Challenges

In the first half of 2026, Bellevue Group achieved a net profit of CHF 1.8 million, navigating through tough market conditions. The firm's assets under management fell by 8.7% to CHF 4.8 billion, largely due to shifts towards the technology sector. Despite this, operating income increased by 4.4% to CHF 26.2 million, supported by positive financial results and reduced operating expenses.

BB Biotech, a key player in the portfolio, saw its market capitalization rise to CHF 2.7 billion, contributing to higher operating income. Strategic cost-reduction efforts from the previous year have begun to materialize, leading to a 3.2% decrease in operating expenses. Additionally, Bellevue Group continues to focus on enhancing efficiency and strategic investments, aiming to capitalize on potential recoveries in the healthcare sector.